Tianjin's biopharmaceutical companies are growing fast, but heavy R&D investment and complex tax matters create compliance pressure. The article highlights companies like Dana Bioscience and Hezhi Pharmaceutical, which embed compliance into the entire R&D process: every project has its own auxiliary ledger, expenses, materials and work hours are tied to project codes, and contracts, invoices and payment records must match before booking, with R&D, HR and tax teams syncing data in real time. Dana enjoyed about 28.9 million yuan in R&D super-deductions last year and has been an A-level taxpayer for eight consecutive years. This digital, intelligent approach to compliance keeps risk at the door and lets innovation move steadily forward.
News Detail
Smart Tax for Risk Prevention: Compliance Drives Innovation
Tianjin's biopharmaceutical industry is booming, but heavy R&D investment and complex tax matters create compliance challenges. The report highlights companies such as Dana Bioscience and Hezhi Pharmaceutical, which embed compliance into the whole R&D lifecycle: each project has its own auxiliary ledger, all expenses and work hours are tied to project codes, and contracts, invoices and payment records must match before booking. Dana paid over 35 million yuan in taxes in 2025, enjoyed R&D super-deductions of about 28.9 million yuan, and has been an A-level taxpayer for eight consecutive years. Hezhi has maintained A-level status for ten years with a closed-loop control of contracts, business, funds and invoices.
2026-08-29